Amplify Transformational Data Sharing ETF vs 10X Genomics Inc — how do they compare? Amplify Transformational Data Sharing ETF trades at $58.96, while 10X Genomics Inc trades at $58.6 (market cap $7.64B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.
| BLOK | TXG | |
|---|---|---|
52-Week High | $74.10 | $58.57 |
52-Week Low | $47.36 | $11.34 |
Market Cap | — | $7.64B |
Sector | — | Health |
Enterprise Value | — | $7.17B |
Signals from Pluang's Aura AI — not financial advice
BLOK trades at $59.89 with minimal daily movement (+0.4%). Technical indicators show a bearish trend with all 13 moving averages signaling sell, while oscillators remain neutral. The stock faces resistance at $60 and support at $59. Recent news highlights the ETF's diversified blockchain economy exposure and inclusion of SpaceX shares following its historic IPO.
The outlook remains cautious due to strong bearish technical signals and sector volatility. Investment opportunity lies in diversified blockchain economy exposure, but risks include market sentiment shifts and competitive ETF landscape. Wall Street sentiment appears mixed with technical weakness offset by strategic positioning in growing sectors.
TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.
The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.
Trailing returns across standard periods
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →